Vaccinex, Inc. Receives Orphan Drug Designation from U.S.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease

ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat patients with cancer and neurodegenerative diseases, today announced that its lead antibody product candidate, VX15, which is currently being investigated in a Phase 2 clinical trial for the treatment of Huntington’s disease (the “SIGNAL” trial), has received Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”).  

The SIGNAL trial is based on the company’s prior research of neurodegenerative disease mechanisms, where it was demonstrated in preclinical models that semaphorin 4D (“SEMA4D”) triggers activation of both microglia and astrocytes, the innate inflammatory cells of the central nervous system.  The chronic activation of microglia and astrocytes has been implicated as a potentially important disease mechanism in HD, progressive multiple sclerosis (“MS”) and other neurodegenerative disorders.  The VX15 antibody is designed to block the functional activity of SEMA4D.  The SIGNAL clinical trial builds upon preclinical studies in an animal model of HD and safety data from a Phase 1 dose-escalation clinical trial of VX15 in MS patients that was completed in November 2014.

“We are pleased to receive Orphan Drug Designation from the FDA for VX15 as a potential treatment for Huntington’s disease.  SIGNAL is an important proof of concept study for the role of inflammation and, in particular, SEMA4D in neurodegenerative processes. We hope that this study will contribute to treatment of HD, a serious disease for which there are, as yet, no approved disease-modifying therapies,” said Maurice Zauderer, Ph.D., Chief Executive Officer of Vaccinex.

The Orphan Drug Act provides for economic incentives to encourage the development of drugs intended to treat, diagnose or prevent rare diseases and conditions affecting (i) fewer than 200,000 people in the United States or (ii) more than 200,000 people in the United States but for which there is no reasonable expectation for recouping development and commercialization costs based on U.S. sales. Orphan drug designation would provide seven years of market exclusivity in the United States, with certain exceptions, if market approval is granted for VX15.  Additional incentives may include tax credits related to clinical trial expenses and waivers from FDA user fees.

About Huntington’s Disease

Huntington’s disease (“HD”) is a hereditary neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain. Symptoms of HD typically begin to manifest in mid-life and worsen over the next 10- to 25-year period. Currently, there are no treatments that can slow or reverse the course of HD. The National Institutes of Health estimates that 30,000 people in the United States have HD. In addition to symptomatic patients, more than 200,000 in the United States carry the gene and are at risk of inheriting the disease.

About Vaccinex, Inc.

Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including Huntington’s disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed and stable in mammalian cells. We believe that recent advances have made this technology uniquely efficient for selection of antibodies against multipass membrane proteins, an important class of target molecules for pharmaceutical development. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex (info@vaccinex.com) or visit www.vaccinex.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements reflecting the current beliefs and expectations of management. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions, as well as other words or expressions referencing future events, conditions or circumstances, are intended to identify forward-looking statements. Forward-looking statements contained in this press release include statements about expectations related to a Phase 2 clinical trial for the Company’s lead monoclonal antibody product candidate, VX15/2503.  Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including as a result of the inherent challenges in clinical development. All forward-looking statements are based on Vaccinex’s expectations and assumptions as of the date of this press release, and actual results may differ materially. Except as required by law, Vaccinex expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Contact: Glen Losev Director, Investor Relations & Corporate Communications Vaccinex, Inc. glosev@vaccinex.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 176

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaker’s TruSend™: A Game Changer in Email Marketing

Updated Category News Views 142

Breaker’s TruSend™: A Game Changer in Email Marketing In the fast-evolving world of marketing, email continues to hold its ground as a vital communication tool. Breaker has recognized the challenges marketers face with fragmented tech stacks and has introduced TruSend™, a robust email distribution platform. This innovation streamlines the email marketing process,...

Continue Reading
DigiKey and Qorvo Collaborate to Enhance Global Distribution

Updated Category News Views 151

DigiKey and Qorvo Forge Strategic Distribution Partnership DigiKey, a prominent global distributor known for its vast selection of technical components and automation products, has entered into a vital distribution agreement with Qorvo®, a leader in connectivity and power solutions. This collaboration aims to boost the availability and delivery speed of Qorvo's...

Continue Reading
Lloyds Bank's Financial Insights for 2025: A Comprehensive Review

Updated Category News Views 345

Overview of Lloyds Bank plc's 2025 Half-Year Results Lloyds Bank plc, a prominent player in the financial services sector, has released its half-year results for 2025, demonstrating resilience and strategic agility. As a member of the Lloyds Banking Group, it continues to show its commitment to delivering value to its stakeholders and customers. Key Financial Highlights...

Continue Reading
Advansor's Latest CO2 Enclosure Solutions Revolutionize Climate Control

Updated Category News Views 97

Advansor Introduces a New Range of CO2 Enclosures Advansor, a leading name in climate solutions, has recently unveiled an innovative line of CO2 enclosures tailored for supermarkets, cold storage facilities, and industrial applications. These enclosures are designed to simplify on-site installations and offer flexible options for outdoor placement. This groundbreaking...

Continue Reading
LG Innotek's Revolutionary Automotive AP Module Enhances Mobility

Updated Category News Views 220

LG Innotek's Innovative Entry into Automotive Semiconductor Market LG Innotek has taken a significant step into the automotive semiconductor component market with the launch of its Automotive Application Processor Module (AP Module). This move comes in response to a growing demand for sophisticated automotive technologies, particularly in the realm of Advanced Driver...

Continue Reading